米卡芬净注射剂治疗侵袭性真菌感染的临床研究  

Clinical trial of micafungin injection in the treatment of invasive fungal infections

作　　者：赵鑫[1] 余愿[1] 袁世荧[1] 付朝晖[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院重症监护病房,武汉430000

出　　处：《中国临床药理学杂志》2016年第24期2235-2238,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察米卡芬净治疗侵袭性真菌感染的临床疗效及安全性。方法收集95例侵袭性真菌感染患者的临床资料,用SPSS 21.0软件对患者治疗前后生命体征、血生化指标及病原菌等指标进行统计分析。结果 95例患者中确诊病例13例(13.68%)、临床诊断病例60例(63.16%)、疑诊病例22例(23.16%),其中治疗成功81例(85.26%),无效14例(14.74%)。治疗前和治疗后,患者的血小板分别为(194.66±127.95)×10~9,(195.76±122.49)×10~9/L;谷丙转氨酶分别为(38.38±31.85),(35.27±26.87)U·L^(-1);谷草转氨酶分别为(57.43±97.23),(39.14±25.19)U·L^(-1);血清肌酸酐分别为(132.55±141.98),(132.05±150.71)μmol·L^(-1),差异均无统计学意义(P>0.05)。治疗前和治疗后,患者的体温分别为(38.06±1.13),(37.17±0.73)℃;白细胞分别为(13.38±7.35)×10~9,(9.01±3.40)×10~9/L;中性粒细胞分别为(16.93±25.60)×10~9,(13.88±22.46)×10~9/L;红细胞沉降率分别为(40.69±35.13),(18.98±8.82)mm·h^(-1);C反应蛋白分别为(55.49±54.95),(18.78±28.98)mg·L^(-1);G试验分别为(161.31±69.01),(25.98±38.62)pg·m L^(-1);GM试验分别为(0.45±0.32),(0.34±0.13),差异均有统计学意义(P<0.05)。95例患者中出现的不良事件与药物相关和可能相关者10例,主要表现为静脉炎、腹泻、头痛、寒战、心悸、皮疹等;出现实验室异常者6例,主要为谷丙转氨酶、尿素氮和血清肌酸酐的轻度增高。结论米卡芬净治疗侵袭性真菌感染的临床疗效显著,且安全性较高。Objective To investigate the efficacy and safety of micafungin in the treatment of invasive fungal infections in intensive care unit （ICU）. Methods A retrospective clinical data about patients admitted to hospital ICU with invasive fungal infections were collected from September 2014 to September 2015 to understand the efficacy and safety of micafungin. Use SPSS 21.0 software for statistical analysis of vital signs, blood biochemistry and pathogens indicators of patients. Results Of 95 patients, 13 （13.68%） cases were the confirmed cases, 60 （63.16%） cases were clinically diagnosed cases, 22 （23.16%） cases were suspected cases; 81 （85.26%） cases achieved the success of treatment, 14 cases （ 14. 74% ） ineffective. Betore and after treatment, platelets were （194.66 ± 127.95） ×10^9, （195.76 ± 122.49）×10^9/L; alanine aminotransferase （ALT） were （38.38 ±31.85）, （35. 27 ±26. 87）U·L^-1; aspartate aminotransferase were （ 57. 43 ± 97. 23 ）, （ 39. 14 ± 25. 19 ） U·L^-1 ; serum creatinine were （ 132. 55 ± 141.98）, （ 132. 05 ± 150. 71 ）μmol·L^-1, there were no statistically significant difference （P 〉 0. 05 ）. Before and after treatment, temperature were （38.06 ± 1.13）, （37. 17 ± 0. 73）℃; leukocytes were （ 13.38 ± 7.35 ）×10^9, （9. 01 ± 3.40 ）×10^9/L; neutrophils were （ 16. 93 ± 25.60 ）×10^9, （ 13.88 ± 22.46 ）×10^9/L; erythrocyte sedimentation rate were （40. 69 ± 35.13 ）, （18.98±8.82）mm·h^-1; C-reactive protein were （55.49±54.95）, （18.78 ±28.98）mg·L^-1; G test were （ 161.31 ±69. 01 ）, （25.98±4.38.62）pg·mL^-1; GM trials were （0. 45 ±0.32）, （0. 34 ±0. 13）, the difference was statistically significant difference （P 〈 0. 05 ）. Adverse events associated with the drug and may be associated were 10 cases, mainly for phlebitis, diarrhea, headache, chills, palpitations, rash, etc ; laboratory abnormalities occurred in 6 patients, primarily ALT, urea nitrogen and serum creat

关 键 词：米卡芬净 侵袭性真菌感染 安全性 

分 类 号：R978.5[医药卫生—药品]